R&D expense · 2011–2025
Emergent Biosolutions R&D expense
$53.2M−24.8% · FY2025
Emergent Biosolutions (EBS) reported $53.2M in R&D expense for fiscal 2025, −24.8% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $53.2M | −24.8% | Open → |
| FY20242024-12-31 | $70.7M | −36.5% | Open → |
| FY20232023-12-31 | $111M | −40.8% | Open → |
| FY20222022-12-31 | $188M | −19.9% | Open → |
| FY20212021-12-31 | $235M | −1.1% | Open → |
| FY20202020-12-31 | $238M | +5.2% | Open → |
| FY20192019-12-31 | $226M | +58.4% | Open → |
| FY20182018-12-31 | $143M | +46.6% | Open → |
| FY20172017-12-31 | $97.4M | −8.9% | Open → |
| FY20162016-12-31 | $107M | −10.3% | Open → |
| FY20152015-12-31 | $119M | +13.8% | Open → |
| FY20142014-12-31 | $105M | −12.7% | Open → |
| FY20132013-12-31 | $120M | −0.2% | Open → |
| FY20122012-12-31 | $120M | −3.7% | Open → |
| FY20112011-12-31 | $125M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth −5.9%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Emergent Biosolutions R&D expense |url=https://companiesranked.com/en/company/emergent-biosolutions/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Emergent Biosolutions R&D expense. CompaniesRanked. https://companiesranked.com/en/company/emergent-biosolutions/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-emergent-biosolutions-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Emergent Biosolutions R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/emergent-biosolutions/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001367644-26-000015 · February 27, 2026
{{cite web |title=Emergent Biosolutions R&D expense — 10-K (0001367644-26-000015) |url=https://www.sec.gov/Archives/edgar/data/1367644/000136764426000015/ebs-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.